Kevin. Thanks,
lead and this Let years it’s committed to four to are privilege to the rewarding company the values. real mission extremely past Nevro’s over vision, and say, dedicated been and talented me who people work just a alongside
evidence. in confidence the advisers treated customers our HFX and And XXX,XXX thank with clinical I over have want who for patients globally also and to belief clinical therapy their
the and in As Kevin I to forward in Nevro entire story, look we in the confidence my exciting supporting full team, chapter I move role. them and have the Nevro’s new into next
quarter on Okay, let’s results first business. over turn to the updates and
in We continue business the the quarter. forward to move
Our revenue our procedure in and EBITDA adjusted exceeded rates both grew digits. and the range U.S. growth guidance results double
growth for really to and pleased leverage believe the they market place going throughout and we blocks am will continue our year and this building becoming are that improving challenges now attractive it’s in I forward to beyond. improve are with and clear that the now
first in Global basis, continues X% was on and U.S. at elements the prior quarter growth. year-over-year in There XX% delivered over be our year. course, growth PDN of a growth U.S. of were while currency growth strong lots came year quarter. of constant activity trial revenue prior with a to growth driver, encouraging progress revenue of significant over XX% XXX% first
U.S. Algorithm. launch patients relief data big launch, personalized full using In March, physicians of the pain regarding iQ in to Since market received we System positive deliver we the feedback began our and from HFX ability our the backed HFX the
remarks, I am in this convinced my our this Now further really competitive differentiate the in opportunity technology has more later but space. on to iQ position
progress All superior builds on paresthesia-free SCS high-frequency our of this technology. of course
in remain and permanent to that largely growth we the encouraging see to the believe continue opportunity implants, fundamentals intact. of underlying for and continue market trials and SCS growth the We addressable
way discussed the linear is before. think, underway recovery to unlikely by I the be as we is that that have in nature
participants three where we very of disclosed share. context four in results main market and SCS particularly that to QX our the pretty market of As their capture U.S. have today, in growth, it’s are pleased clear the that continue with we
digits, business to encouraged move am the total has direction. recovery, for fact for row a this grew a continued that market which is quarter the in equally it that bodes participants SCS I in high-single as these the well by positive second the in other
round approximately completed volume we they of SCS QX with said SCS they nearly their therapy market physicians are In increase and of XXXX. physicians in physician surveyed research, to said another satisfied all XX% want
SCA their -- compared expect they volume grow said XX% roughly Additionally, year this volume year. to prior SCS to
said physicians challenges staffing the are at to declining. lingering in be the to having of challenges ongoing Not such issues also actual surprisingly, pain experience they on payer volumes staffing majority a then continue but and pressure impact space, appears as
when patients Remember last late relief chronic SCS are either a conservative option. surgeries not used just their options optimal relieve treatment to is don’t or and an provide therapy more considered or simply of line pain even
We but the pace seen we of slowed of the move from treatment recovery and pandemic and funnel. pain indicators have patients the through issues which the positive that patients pandemic lingering some research know entering from pathway, treatment including had previous the at growth that
with had than XXXX, visit physicians and the equal greater patient last us patient were Physicians told of to/or in stating pre-pandemic that XXXX volumes pain in visits leg their volumes back XX% approximately year. improved
They volumes had ultimately visit also QX indicated or of SCS this grown for XXXX. trend level is well of bodes the their continuing customer’s with compared the practices patient just XX% to We this over to continued of same in our stay stating QX market. patients returning recovery believe quarter prior
with return and are make and appointments pain the comfortable to ready see their through pathway are SCS As move treatment continuing market to the specialists growth more historical patients rates. who we for patients
our total of trial XX% approximately represented up the the percentage and quarter. trials PDN business. U.S. PDN of year. our U.S. improved in to actually volume last turning XX% throughout from Now trial of of our QX course total That’s volume that
Among of the increase to quarter approximately implant year. of XXX%, total million represented compared PDN that’s resulting an million PDN our last first permanent in the $XX.X procedures, procedures, sales worldwide indication XX% and $X in in of
last in sales this referral was June. attribute We measure large organization PDN expansion that to completed the
and initiatives and otherwise world difficult real Our physicians and treat regarding patients. general in patients, outreach compelling outcomes the data to to enthusiasm these direct the
XX of XX to sales Our PDN about our to to increase the from by continue of around this is that’s the at end XXXX. end referral current up year, footprint plan team so or
successes March We of and trials see well. PDN generated QX record PDN direct-to-patient of for approximately leads. DTC from a by these In procedures number our DTC leads XX% our our to the of from U.S. month programs PDN continue with in came came marketing as trial
case are PDN high through a payers PDN, payer and policy by approvals who to place. addition don’t authorization see payer coverage existing level including of with for process have the prior the positive that denials, we appeal place continue in of to in case the policies a coverage In
and at through PDN cases that at the our those to approval own up about from XX-month come have rate XX% end was rolling group, the XX% trend access our of of end around QX continue that XXXX. For
clinical payer based denial strong we patient of able indication over through success In resulting our the case approved inclusion patient and half are leverage published various our appeals guidelines in denials, FDA in group. submit of evidence in making approval our PDN access we for data, society to arguments
RCT pain function Neurology well the data Dr. as of therapy. improvement at week, these Academy long-term as XX durability the in in Earlier presented PDN XX-month life of neurological with this Conference clinically Petersen at the quality kilohertz results complete meaningful confirm Boston. and American relief, And Erika of achieved
our investigators all of in this participated of trial. We distinction the PDN XX-month who landmark by data for Petersen PDN was AAN Dr. the and honored selected that congratulate a were and merit Senza
interests to the category, to neurologic based awarded is the Distinction community. of in and the abstract topic each top study on quality rated
event We to data PDN this expect publication. quarter RCT for this complete XX-month
In assess staggering specifically in is treatment this and pose of available which is in enrolled for prospective with the our socioeconomic a Sensory powered Study, option patients peripheral PDN. available a and there endpoint as patient Diabetes PDN restoration patients addition, neurological Intractable to primary function we disease first quarter our burden no PDN. RCT neuropathy new modifying with first
disease course, By kilohertz feet and XX reduce may in life, SCS all to costs. of amputations burden, prevent patients sensation quality health enable and the restoring and would of improve tremendous more active of which overall therapy healthcare alleviate be this
reported observed neurological low been are for to therapy. unique competitive original PDN XX in recall saw SCS kilohertz study that we Senza the frequency the other any SCS have will therapy You not improvements
leave add the break the that out before for made PDN PDN, first to me launch. critical sense us in of I has commercial stages it Now let
disparate disclosure to we team evaluating make be segment Moving the all further other I us approach here serve do not business to forward at two SCS sense. label and of all, PDN not now will am sure continues this on if After who competitively. and Kevin their well have reporting competitors levels
Stem whether replacement neck Remember PDN their et some cell unreported volumes, Nerve PNS of DRG that it’s or and pain, different Peripheral even even versus in limb each NSBP, or volumes, competitors cetera. leg pain utilization, segments our have implants, primary upper business, back
and All not they which are reported simply broken of of out SCS share. part their are as
by And of the all to the and treat service and deployed are the chronic these by pain. same the truth implanting indications same SCS physicians use technology same organization is are sold
driving overall gains share just we and growth and are doing We are in that. period company interested market
This significant non-surgical and Moving We important a reported data our XX improvement. for life submitted NSBP data two-year as patients as publication. relief improvement the pain and kilohertz treated quality of pain. now back with SCS, in function to strong from clinically included durable trial well in stable
pain all low-back chronic surgical nonoperative refractory candidacy medical with patients exhausted spine surgeon were in who appropriate seen evaluated were results These management. who a for and by had
Once second therapy fulsomely of see to about of will carriers the NSBP. this publish published expect for these with We benefits in more year. this half commercial enable data engage to us the HFX
the coverage coverage in coverage continues On indication us front for our two the added quarter, commercial coverage additional to XX% carriers health bringing Cross PDN. to patients nearly Blue of offering new PDN Blue PDN plans grow Shield with first
Assuming contractors with last Medicare their two administrative covered pending just coverage. XX% increase to Novitas coverage and First lives. Total the coverage finalize Coast, of determinations will local proposed over PDN
pain as basis PDN not With on failed The specifying back regard remain our for NSBP any NSBP we in to patients. other a coverage traditional rates impact experienced leg any health patients. for revenue have plans surgery with and noticeable NSBP, and to-date consistent on such approval case-by-case back from indications not
like I’d that first iQ cord stimulation Senza patient’s time of our we AI-powered the by the full device the release is backed therapy. U.S. pain new initiated each to over data system the March, and experience interaction received. big been and iQ gets really patients iQ with to HFX from the market that spinal turn In that learning Now, in well System. smarter has
pain their them. big real their experience basis This of that input therapy their suits is a and intended really more time control patients at optimize based and combination patient relief and direct and engaging AI personal over maintain relief clinical world in to and patients individualized an on giving on data, engagement
beyond. powerful with patients customers our XXXX to physicians expect our iQ that and our data. our field outcomes iQ in lessen launch is database team, this the We and and cloud that both our detailed well coaches HFX and growth provides prospects summary burden our to supplement and will on a support believe
team product a in is forward. it our As going we over to enables also us pointed revenue cost iQ allowing step patients out the line of attractive existing logical before as and scale a a base larger growth, more drive of to
ramp of our earnings I help years. in up the really the with Rica to our going productivity think that this Costa on with combined revenue coming is facility growth manufacturing us
customers, full launch anecdotal of early as quite current on the devices Although still in competitive days feedback iQ well has as been use from positive. physicians
found input iQ daily HFX XX% and surveyed System treating indicated achieve our they of personalized App very using During to pain entering XX% earlier required. pain their of the limited questions the do. satisfied easy market chronic release physicians in patients the relief, patients through of was to their patients XX% also agreed
does to our Not therapy narrative to product how relief maintained it’s can optimized but AI-enabled new with customers, team the opportunity our exciting and changing only give algorithm SCS their around delivered, provide the an iQ sales to patients. treatment also using discuss be
that One of that patient’s put hand. experience all iQ the power physician felt and of the into up recently thousands saying programming of that of all summed by and he outcomes from XXs harness clinical patients the form
functionality with the patient continue digital that add we optimize new product app. experience over new to and improves the with any time features As will launch
and our implant of In for expect already full iQ meaningful underway, throughout the of product QX, a the about HFX of with accounted shift year. HFX rest permanent the in XX% iQ iQ to mix the launch we procedures
chronic for keeps as our the pain technology, innovation, firmly new deliver to life-changing summary, to customers the continue commitment Nevro forefront at of to indications new and our new to comprehensive, with our iQ data solutions In bring patients reflects and patients. and continued it we
like be the PDN made we believe platform, very a leverage iQ structure. and new quarter, the HFX what progress closing, patient with NSBP, will markets, such encouraging expense operating I in the important attractive think scalability as on recovery continued first is entirely products opportunity of our we in what the focus and So, on future for growth populations intense as new result our our of in
of best forward. the all outlook and the days best our Nevro are us, think wish ahead bright I I entire Kevin team and and Nevro increasingly is the going for
and call with quarter that, guidance. to over further pass And on first results will I details the provide our our Rod to
